Ixazomib Benefit Persists Despite Prior Therapy in TOURMALINE-MM1 Subset Analysis
María-Victoria Mateos, MD, PhD, shares the results of a subset analysis of TOURMALINE-MM1, which showed that patients with prior exposure to proteasome inhibitors still benefited from ixazomib treatment.
The U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application for ponatinib to treat adults with chronic-phase chronic myeloid leukemia...
Achievement of measurable residual disease (MRD) negativity is associated with significant improvements in progression-free survival (PFS) and overall survival (OS) in patients with multiple...
The FDA has approved selinexor in combination with bortezomib and dexamethasone (Vd) for the treatment of adults with multiple myeloma (MM) who have received...
The Special Symposium on Quality at the 2020 ASH Annual Meeting tackled an often-overlooked driver of quality of patient care: burnout. Physician burnout –...